Larimar Therapeutics, Inc.(LRMR)

$3.83—

Chart

Larimar Therapeutics, Inc.(LRMR)

NASDAQ

$3.83—

Chart Studio

LRMR(LRMR)

LRMR

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.39

Nov 5, 2026 · Reports before open

FY2029E EPS$1.03

FY2030E EPS$2.41

Analyst Sentiment

Wall St. Consensus

Buy

8 analysts·Limited coverage

Score

8 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

8100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$5.00

+30.5%

Consensus

$8.00

+108.9%

Bull

$11.00

+187.2%

12-Month Target Range8 analysts

$5.00$8.00$11.00

Current $3.83Consensus

Current Price

$3.83

Upside to Consensus

$4.17

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+1700.13%

EPS—

FY2028

Rev+212.54%

EPS—

FY2029

Rev+240.26%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$2M	$42M	$130M	$444M	$660M
Low	$486,247	$7M	$29M	$93M	$139M
High	$6M	$70M	$277M	$1.17B	$1.74B
EBITDA Avg	$-107M	$-85M	$-51M	$95M	$223M
Low	$-122M	$-113M	$-103M	$-2M	$-5M
High	$-92M	$-57M	$-6M	$297M	$695M
EBIT Avg	$-107M	$-85M	$-52M	$95M	$223M
Low	$-123M	$-113M	$-103M	$-2M	$-5M
High	$-92M	$-57M	$-6M	$297M	$695M
Net Income Avg	$-107M	$-85M	$-52M	$75M	$176M
Low	$-123M	$-113M	$-103M	$-2M	$-5M
High	$-92M	$-57M	$-6M	$235M	$549M
EPS Avg	$-1.40	$-1.22	$-0.59	$1.03	$2.41
Low	$-1.68	$-1.55	$-1.41	$-0.03	$-0.07
High	$-1.26	$-0.78	$-0.08	$3.22	$7.53
Analysts (Rev / EPS)	7 / 7	8 / 7	7 / 5	3 / 1	5 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	—	$2M	—	$30M	$6M	$18M
Low	—	$2M	—	$30M	$6M	$18M
High	—	$2M	—	$30M	$6M	$18M
EBITDA Avg	—	$-41M	—	$-25M	$-39M	$-30M
Low	—	$-49M	—	$-25M	$-39M	$-30M
High	—	$-35M	—	$-25M	$-39M	$-30M
EBIT Avg	—	$-41M	—	$-25M	$-39M	$-30M
Low	—	$-49M	—	$-25M	$-39M	$-30M
High	—	$-35M	—	$-25M	$-39M	$-30M
Net Income Avg	$-37M	$-41M	$-42M	$-25M	$-39M	$-30M
Low	$-47M	$-49M	$-42M	$-25M	$-39M	$-30M
High	$-32M	$-35M	$-42M	$-25M	$-39M	$-30M
EPS Avg	$-0.35	$-0.39	$-0.40	$-0.24	$-0.37	$-0.29
Low	$-0.45	$-0.47	$-0.40	$-0.24	$-0.37	$-0.29
High	$-0.31	$-0.33	$-0.40	$-0.24	$-0.37	$-0.29
Analysts (Rev / EPS)	— / 6	1 / 6	— / 2	1 / 2	1 / 2	1 / 2

Earnings Surprises

Recent Analyst Actions

Aug 5, 2026Wedbush

Larimar Therapeutics price target lowered to $11 from $12 at Wedbush

Target:$11.00

+160.0%from $4.23

Jun 30, 2026Robert W. Baird

Larimar Therapeutics price target lowered to $5 from $7 at Baird

Target:$5.00

+56.2%from $3.20

Mar 3, 2026Wedbush

Larimar Therapeutics (LRMR) PT Raised to $12 at Wedbush

Target:$12.00

+119.2%from $5.47

Sep 30, 2025Robert W. Baird

Larimar Therapeutics price target lowered to $7 from $10 at Baird

Target:$7.00

+107.1%from $3.38

Dec 17, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Target:$15.00

+250.5%from $4.28

Oct 30, 2024Citigroup

Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR), Opens 90-Day Upside Catalyst Watch

Target:$14.00

+65.5%from $8.46

Oct 3, 2024Wedbush

Wedbush bullish on Larimar Therapeutics, initiates with an Outperform

Target:$22.00

+249.8%from $6.29

Apr 3, 2024Leerink Partners

Leerink bullish on Larimar Therapeutics, initiates with an Outperform

Target:$25.00

+230.3%from $7.57

Dec 13, 2022Citigroup

Citigroup Initiates Coverage On Larimar Therapeutics with Neutral Rating, Announces Price Target of $4

Target:$4.00

+0.8%from $3.97

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance